Key result
123I-MIBG imaging links comorbidities to worse sympathetic nervous system impairment in HF.
Why the study?
Assessing myocardial sympathetic innervation is central to prognosis in heart failure, motivating a summary of recent evidence on 123I-MIBG imaging in heart failure and related comorbidities.
Does 123I-MIBG imaging help evaluate cardiac sympathetic neuronal function and assess risk stratification in patients with heart failure and related comorbidities?
Does 123I-MIBG imaging help evaluate cardiac sympathetic neuronal function and assess risk stratification in patients with heart failure and related comorbidities?
123I-MIBG imaging is a useful tool for evaluating sympathetic nervous system impairment and risk stratification in heart failure patients, particularly those with comorbidities.
Comorbidities may worsen sympathetic impairment on 123I-MIBG in HF; leaves open prospective validation for refined risk stratification.
Purpose Heart failure (HF) is a primary cause of morbidity and mortality worldwide, with significant impact on life quality and extensive healthcare costs. Assessment of myocardial sympathetic innervation function plays a central role in prognosis assessment in HF patients. The aim of this review is to summarize the most recent evidence regarding the clinical applications of iodine-123 metaiodobenzylguanidine ( 123 I-MIBG) imaging in patients with HF and related comorbidities. Methods A comprehensive literature search was conducted on PubMed and Web of Science databases. Articles describing the impact of 123 I-MIBG imaging on HF and related comorbidities were considered eligible for the review. Results We collected several data reporting that 123 I-MIBG imaging is a safe and non-invasive tool to evaluate dysfunction of cardiac sympathetic neuronal function and to assess risk stratification in HF patients. HF is frequently associated with comorbidities that may affect cardiac adrenergic innervation. Furthermore, HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney disease and others, that may affect cardiac adrenergic innervation. Conclusion Comorbidities and chronic conditions lead to more severe impairment of sympathetic nervous system in patients with HF, with a negative impact on disease progression and outcome. Cardiac imaging with 123 I-MIBG can be a useful tool to reduce morbidity and prevent adverse events in HF patients.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2022) conducted a review in Heart failure. 123I-MIBG imaging was evaluated. Cardiac imaging with 123I-MIBG demonstrates that comorbidities such as diabetes, obesity, and kidney disease lead to more severe impairment of the sympathetic nervous system in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: